Nicox (LSE:0RCQ) - Stock Price, News & Analysis

0RCQ Stock Overview

Nicox S.A. operates as an ophthalmology company in France and internationally.

0RCQ fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Revenue is forecast to grow 65.8% per year

Risk Analysis

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap (€19M)

Does not have meaningful revenue (€4M)

Nicox S.A. Competitors

Oncimmune Holdings

AIM:ONC

UK£19.6m

OptiBiotix Health

AIM:OPTI

UK£17.6m

ProBiotix Health

OFEX:PBX

UK£6.4m

Arecor Therapeutics

AIM:AREC

UK£39.4m

Price History & Performance

Summary of all time highs, changes and price drops for Nicox
Historical stock prices
Current Share Price	€0.40
52 Week High	€0.62
52 Week Low	€0.32
Beta	0.89
1 Month Change	0%
3 Month Change	-3.81%
1 Year Change	-34.97%
3 Year Change	-90.15%
5 Year Change	-92.61%
Change since IPO	-99.30%

Recent updates

Shareholder Returns

	0RCQ	GB Biotechs	GB Market
7D	0%	-2.4%	-1.4%
1Y	-35.0%	-29.6%	-2.4%

Return vs Industry: 0RCQ underperformed the UK Biotechs industry which returned -30.1% over the past year.

Return vs Market: 0RCQ underperformed the UK Market which returned -0.8% over the past year.

Price Volatility

Is 0RCQ's price volatile compared to industry and market?
0RCQ volatility
0RCQ Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.5%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	11.5%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: 0RCQ has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 0RCQ's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1996	28	Gavin Spencer	www.nicox.com

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.

Nicox S.A. Fundamentals Summary

How do Nicox's earnings and revenue compare to its market cap?
0RCQ fundamental statistics
Market cap	€18.63m
Earnings (TTM)	-€17.36m
Revenue (TTM)	€3.57m

5.2x

P/S Ratio

-1.1x

P/E Ratio

Is 0RCQ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0RCQ income statement (TTM)
Revenue	€3.57m
Cost of Revenue	€16.90m
Gross Profit	-€13.33m
Other Expenses	€4.03m
Earnings	-€17.36m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.35
Gross Margin	-372.97%
Net Profit Margin	-485.70%
Debt/Equity Ratio	44.8%

How did 0RCQ perform over the long term?

See historical performance and comparison

0RCQ Stock Overview

Rewards

Risk Analysis

Nicox S.A. Competitors

AIM:ONC

UK£19.6m

AIM:OPTI

UK£17.6m

OFEX:PBX

UK£6.4m

AIM:AREC

UK£39.4m

Price History & Performance

Recent News & Updates

Nicox SA Receives Confirmation of 5-Year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA

Nicox's Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 Compared to Lumigan

First half 2023 earnings released: €0.13 loss per share (vs €0.39 loss in 1H 2022)

New major risk - Revenue and earnings growth

Nicox S.A. to Report Q2, 2023 Results on Jul 19, 2023

Full year 2022 earnings released

Recent updates

Nicox SA Receives Confirmation of 5-Year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA

Nicox's Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 Compared to Lumigan

First half 2023 earnings released: €0.13 loss per share (vs €0.39 loss in 1H 2022)

New major risk - Revenue and earnings growth

Nicox S.A. to Report Q2, 2023 Results on Jul 19, 2023

Full year 2022 earnings released

Nicox S.A., Annual General Meeting, Feb 28, 2023

Nicox S.A., Annual General Meeting, Feb 14, 2023

Nicox S.A. Outlines Future Development and Partnering Plans for Ncx 470 in Glaucoma

Nicox S.A. Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470

Nicox S.A. Announces Last Patients Complete Final Visit in Ncx 470 Phase 3 Mont Blanc Glaucoma Trial

First half 2022 earnings released: EPS: €0 (vs €0.32 loss in 1H 2021)

Nicox Appoints Jean-Francois Labbé as Chairman of the Board of Directors

Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiology

Nicox S.A., Annual General Meeting, Jun 28, 2022

Nicox S.A. Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to November 2022

Nicox S.A. Announces Executive Changes

Nicox S.A., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings released: €1.17 loss per share (vs €0.54 loss in FY 2020)

Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma

Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE® in China

Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 Countries

Nicox S.A. Announces Chinese National Intellectual Property Administration Grant A Formulation Patent for NCX 470

Nicox’s Positive FDA Meeting Shows Clear Path for NCX 4251 in Dry Eye

Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucoma

Nicox S.A. Announces Positive Post Hoc Results from Its Mississippi Phase 2B Clinical Trial Suggesting That Once-Daily Dosed NCX 4251

Nicox SA Reports New Data on NCX 470 in Nonclinical Model of Retinal Cell Damage Induced by Endothelin-1

First half 2021 earnings released

Nicox S.A. Announces Results from the NCX 4251 Phase 2B Mississippi Blepharitis Trial

High number of new and inexperienced directors

Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2B Blepharitis Trial

Nicox SA Presented Results from the Dolomites Phase 2 Clinical Trial Showing That NCX 470

Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates

Nicox SA to Present NCX 470 Dolomites Phase 2 Results in Glaucoma Patients at the World Glaucoma E-Congress 2021

Nicox's Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Trial

Nicox’s Licensee Bausch + Lomb Launches VYZULTA® (Latanoprostene Bunod Ophthalmic Solution), 0.024% in Taiwan and Receives Approval in Qatar

U.S. Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucoma

Nicox S.A., Annual General Meeting, Apr 14, 2021

Full year 2020 earnings released

Nicox S.A. to Report Fiscal Year 2020 Results on Mar 01, 2021

Nicox Announces the Publication in Leading Scientific Journal of Pre-Clinical Efficacy Results on a New Class of Non-PGA NO-donating IOP-Lowering Compounds

Nicox S.A. Licensee Bausch + Lomb Secures Approval of VYZULTA in Colombia

Nicox Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for Blepharitis

Nicox’s Partner Fera Pharmaceuticals to Investigate Naproxcinod as Potential Covid-19 Adjuvant Treatment

Nicox S.A. has completed a Follow-on Equity Offering in the amount of €15.000651 million.

Nicox SA Initiates Second Phase 3 Trial of NCX 470 in Glaucoma

Nicox Announces Plans for NCX 4251 Phase 2 Trial in Blepharitis

Nicox Selects 0.1% NCX 470 Dose in Adaptive Stage of Mont Blanc Phase 3 Glaucoma Trial

Nicox SA Nicox Announces Senior Management Change

Nicox S.A. to Report First Half, 2020 Results on Sep 10, 2020

GHO Capital Fund I LP managed by GHO Capital Partners LLP entered into an agreement to acquire remaining unknown minority stake in VISUfarma B.V from Nicox S.A. (ENXTPA:COX) for €5 million